Role of the kisspeptin-KISS1R axis in the pathogenesis of chronic kidney disease and uremic cardiomyopathy

• Published in: GeroScience 2024-04, Vol.46 (2), p.2463-2488
• Main Authors: Dinh, Hoa, Kovács, Zsuzsanna Z. A., Kis, Merse, Kupecz, Klaudia, Sejben, Anita, Szűcs, Gergő, Márványkövi, Fanni, Siska, Andrea, Freiwan, Marah, Pósa, Szonja Polett, Galla, Zsolt, Ibos, Katalin Eszter, Bodnár, Éva, Lauber, Gülsüm Yilmaz, Goncalves, Ana Isabel Antunes, Acar, Eylem, Kriston, András, Kovács, Ferenc, Horváth, Péter, Bozsó, Zsolt, Tóth, Gábor, Földesi, Imre, Monostori, Péter, Cserni, Gábor, Podesser, Bruno K., Lehoczki, Andrea, Pokreisz, Peter, Kiss, Attila, Dux, László, Csabafi, Krisztina, Sárközy, Márta
• Format: Article
• Language: English
• Subjects: Age; Aged; Animals; Apoptosis; BAX protein; Bcl-2 protein; Biomedical and Life Sciences; Blood pressure; Cardiomyocytes; Cardiomyopathies - complications; Cardiomyopathy; Cell Biology; Fibrosis; Geriatrics/Gerontology; Heart; Humans; Hypertension - complications; Hypertrophy; Inflammation; Kidney diseases; Kiss1 protein; Kisspeptins; Life Sciences; Male; Molecular Medicine; Nephrectomy; Original; Original Article; Pathophysiology; Rats; Rats, Wistar; Receptors, Kisspeptin-1; Renal Insufficiency, Chronic - complications; Ventricle
• ISSN: 2509-2723; 2509-2715; 2509-2723
• DOI: 10.1007/s11357-023-01017-8

The prevalence of chronic kidney disease (CKD) is increasing globally, especially in elderly patients. Uremic cardiomyopathy is a common cardiovascular complication of CKD, characterized by left ventricular hypertrophy (LVH), diastolic dysfunction, and fibrosis. Kisspeptins and their receptor, KISS1R, exert a pivotal influence on kidney pathophysiology and modulate age-related pathologies across various organ systems. KISS1R agonists, including kisspeptin-13 (KP-13), hold promise as novel therapeutic agents within age-related biological processes and kidney-related disorders. Our investigation aimed to elucidate the impact of KP-13 on the trajectory of CKD and uremic cardiomyopathy. Male Wistar rats (300–350 g) were randomized into four groups: (I) sham-operated, (II) 5/6 nephrectomy-induced CKD, (III) CKD subjected to a low dose of KP-13 (intraperitoneal 13 µg/day), and (IV) CKD treated with a higher KP-13 dose (intraperitoneal 26 µg/day). Treatments were administered daily from week 3 for 10 days. After 13 weeks, KP-13 increased systemic blood pressure, accentuating diastolic dysfunction’s echocardiographic indicators and intensifying CKD-associated markers such as serum urea levels, glomerular hypertrophy, and tubular dilation. Notably, KP-13 did not exacerbate circulatory uremic toxin levels, renal inflammation, or fibrosis markers. In contrast, the higher KP-13 dose correlated with reduced posterior and anterior wall thickness, coupled with diminished cardiomyocyte cross-sectional areas and concurrent elevation of inflammatory ( Il6, Tnf ), fibrosis ( Col1 ), and apoptosis markers ( Bax/Bcl2 ) relative to the CKD group. In summary, KP-13’s influence on CKD and uremic cardiomyopathy encompassed heightened blood pressure and potentially activated inflammatory and apoptotic pathways in the left ventricle.